Coming soon HCI-024 PDX
Breast cancer patient derived xenograft PDX
Contributors
| Inventor | Institute |
|---|---|
| Alana L Welm, Yi-Chun Lin, Yoko Sakata DeRose | The University of Utah Research Foundation |
| SKU: | 162090 |
|---|---|
| Product description: |
Please register your interest through the enquiry button (quote not currently available) Human breast cancer-derived xenograft that retains high fidelity to original tumour and provides valuable resources for drug discovery and precision oncology. This panel of Patient Derived Xenografts provide models for some of the deadliest forms of breast cancer including drug-resistant, metastatic tumours, and endocrine-resistant estrogen receptor-positive (ER+) and HER2+ tumours. S… |
| Cat. #: | 162090 |
|---|---|
| Cancer types: | Breast cancer |
| Cancer Subtype: | Infiltrating Ductal Carcinoma |
| Gender: | Female |
| Biopsy Site: | Skin metastasis |
| Patient ethnicity: | Caucasian |
| Treatment History: | Pretreated: Patient had not undergone radiation therapy but received systemic treatment of doxorubicin, cyclophosphamide, and paclitaxel 2014-2015 prior to sample collection |
| Primary citation: | Guillen, et al. 2022. Nature Cancer. Feb; 3(2):232-250. PMID: 35221336 |
| Initial handling information: | Implant into the cleared inguinal mammary fat pad of female Immune-compromised mice NSG. NSG (fresh) time to growth: 8 months to 2 cm. |
|---|---|
| Additional notes: | Additional Information on PDX establishment: https://www.nature.com/articles/s43018-022-00337-6/figures/9 |
| Mice Passaged: | Yes |
|---|---|
| Engraftment Site: | Cleared mammary fat pad |
| Host Strain: | Immunocompromised mice NOD scid gamma (NSG) Jackson Laboratory 5557; NOD/scid, Jackson Laboratory 1303 or NOD rag gamma (NRG), Jackson Laboratory 7799 |
| Histology: | PAM50 subtype Basal-like |
| Production details: | Fresh or thawed human breast tumour fragments were implanted into the cleared inguinal mammary fat pad of female Immune-compromised mice. For bone metastasis samples, bone fragments were coimplanted. For liquid specimens, pleural effusion, or ascites fluid, 1-2 milion cells were injected into cleared mammary fat pads in Matrigel. For ER+ tumours, mice were dosed with E2 beeswax pellets and given supplemental E2 via drinking water. When tumours reached 1-2 cm in diameter, tumours were aseptica… |
| References: |
Tufail, et al. 2024. Journal of Translational Med. Jan 3:22(1):15. PMID: 38172946 Bhattacharya, et al. 2023. Journal of Experimental & Clinical Cancer Research. Dec 16:42(1):343. PMID: 38102637 Prekovic, et al. 2023. EMBO Molecular Medicine. Dec 7:15(12):e17737. PMID: 37902007 Daneshdoust, et al. 2023. Cells. Sep 30:12(19):2338. PMID: 37830602 Wang, et al. 2023. Cell Bioscience. Dec 1:13(1):224. PMID: 38041134 Guillen, et al. 2022. Nature Cancer. Feb 3(2):232-250. PMID: 35221336 |
|---|
Related Tools for PDX models
| Cat. # | Tool Name | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 151146 | Anti-p53 [Pab 240] |
Key Info
Anti-p53 [Pab 240]
|
View Tool | |||||||||||||||||||
| 152698 | Anti-PALB2 [M41-P3F3] |
Key Info
Anti-PALB2 [M41-P3F3]
|
View Tool | |||||||||||||||||||
| 156496 | Anti-pS114-BRCA1 [3C10G8] |
Key Info
Anti-pS114-BRCA1 [3C10G8]
|
View Tool | |||||||||||||||||||
| 162076 | HCI-008 breast cancer PDX |
Key Info
HCI-008 breast cancer PDX
|
View Tool | |||||||||||||||||||
| 162077 | HCI-009 breast cancer PDX |
Key Info
HCI-009 breast cancer PDX
|
View Tool | |||||||||||||||||||
